Is late-onset multiple sclerosis associated with a worse outcome?

Neurology

Volumn 67, Issue 6, 2006, Pages 954-959

  Tremlett, Helen ^a   Devonshire, Virginia ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISABILITY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; ONSET AGE; OPTIC NERVE DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RISK FACTOR; SENSORY NEUROPATHY; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; AGED; CHI-SQUARE DISTRIBUTION; COMMUNITY HEALTH PLANNING; DEMOGRAPHY; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33749014399     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000237475.01655.9d     Document Type: Article

References (36)

1. Martinelli V, Rodegher M, Moiola L, Comi G. Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci 2004;25(suppl 4):S350-355.
2. Paty DW, Ebers GC. Multiple sclerosis. Philadelphia: F.A. Davis, 1998.
3. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
4. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research proposals. Ann Neurol 1983;13:227-231.
5. Polliack ML, Barak Y, Achiron A. Late-onset multiple sclerosis. J Am Geriatr Soc 2001;49:168-171.
6. Bauer HJ, Hanefeld F. Multiple sclerosis: its impact from childhood to old age. London: W.B. Saunders, 1993.
7. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438.
8. White AD, Swingler RJ, Compston DA. Features of multiple sclerosis in older patients in South Wales. Gerontology 1990;36:159-164.
9. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146.
10. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004;62:51-59.
11. Phadke JG. Clinical aspects of multiple sclerosis in north-east Scotland with particular reference to its course and prognosis. Brain 1990;113:1597-1628.
12. Noseworthy J, Paty D, Wonnacott T, Feasby T, Ebers G. Multiple sclerosis after age 50. Neurology 1983;33:1537-1544.
13. Cazzullo CL, Ghezzi A, Marforio S, Caputo D. Clinical picture of multiple sclerosis with late onset. Acta Neurol Scand 1978;58:190-196.
14. Paty D, Boiko A, Vorobeichik G. Multiple sclerosis with early and late disease onset. In: McDonald WI, Noseworthy J, eds. Multiple Sclerosis 2. Boston: Butterworth Heinemann, 2003:285-302.
15. Hooge JP, Redekop WK. Multiple sclerosis with very late onset. Neurology 1992;42:1907-1910.
16. Compston A, Coles AJ. Multiple sclerosis. Lancet 2002;359:1221-1231.
17. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006;66:172-177.
18. Liguori M, Marrosu MG, Pugliatti M, et al. Age at onset in multiple sclerosis. Neurol Sci 2000;21:S825-829.
19. Statistics Canada. Population by selected ethnic origins, by provinces and territories (1996 Census). Available at: http://www.statcan.ca/english/Pgdb/ demo28c.htm. Accessed January 4, 2005.
20. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005;65:1914-1923.
21. de Seze J, Delalande S, Michelin E, et al. Brain MRI in late-onset multiple sclerosis. Eur J Neurol 2005;12:241-244.
22. Kurtzke J. Rating neurologic impairment in Multiple Sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
23. Wolfson C, Wolfson DB. The latent period of multiple sclerosis: a critical review. Epidemiology 1993;4:464-470.
24. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease. Brain 2006.
25. Sim FJ, Zhao C, Penderis J, Franklin RJ. The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. J Neurosci 2002;22:2451-2459.
26. Lu T, Pan Y, Kao SY, et al. Gene regulation and DNA damage in the ageing human brain. Nature 2004;429:883-891.
27. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind placebo-controlled trial. Neurology 1995;45:1268-1276.
28. Comi G, Filippi M, Wolinsky JS, the European and Canadian Glatiramer Acetate Study Group.. European/Canadian multi-center doubleblind, randomized placebo controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.
29. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology 1999;53:679-686.
30. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multi-center, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
31. Placebo-controlled multi-center randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998;352:1491-1497.
32. Polman C, Barkhof F, Kappos L, et al. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Mult Scler 2003;9:342-348.
33. Secondary progressive Efficacy Clinical Trial of recombinant interferon-beta-1a in MS (SPECTRIMS) study group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Neurology 2001;56:1496-1504.
34. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
35. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-1795.
36. Miller D, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing MS. N Engl J Med 2003;348:15-23.